Customized research for NAVB vs. ACRX!

All in one page research, scroll down. Compare two other stocks.

Note: Don't forget to explore SpeculatingStocks further... from the SpeculatingStocks.com Homepage you can Discover Stocks, Post Anonymously, and React. No Login Required.

Done! Side by Side Research Below for NAVB vs. ACRX.


↗ Join Our Free Email Newsletter.




Your Mobile Phone Number:

Navidea Biopharmaceuticals, Inc vs. AcelRx Pharmaceuticals, Inc.

Industry Match! Industry of Both NAVB and ACRX:

Health Care/Life Sciences

NAVB
Data Last Updated: 15 hours ago

↻  Update Column 1 to Most Recent

Key Statistics

Cap: 125.956M


P/E: N/A

P/S: 190.84

Q P/B: N/A

Y Rev: 657,826

Q Rev: 156,272

Beta: 1.96

NAVB Share Stats

Outstanding Shares

25.45M

Float Shares

17.95M

Percent of Float Short

2.01%

NAVB Insider Stats

Percent Outstanding Insider Ownership

84.8%

Percent Outstanding Institution Ownership

3.28%

NAVB Social Stats

Followers

0

B/S Rating Today

0

B/S Rating All-Time

N/A

More Social Data

NAVB in Pulse Portal

Stream of Posts

NAVB Symbol Page

Share NAVB Insights

Express Sentiment

'Buy' or 'Sell' NAVB

NAVB Profile

CEO

Mr. Jed Andrew Latkin

Exchange

NYSE American

Employees

17.00

About

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is...

NAVB Financials

Annual Financials

Income Statement

Revenue

657,826

Net Income

(10.95M)

Cash Flow Statement

Change in Cash / Investments

(2.43M)

Balance Sheet

Cash / Investments

1.05M

Short Term Debt

556,508

Long Term Debt

None

Total Current Assets

2.92M

Total Current Liabilities

3.82M

Total Assets

4.15M

Total Liabilities

5.03M

Stockholder Equity

(1.61M)

Quarterly Financials

Income Statement

Q Revenue

156,272

Q Net Income

(2.67M)

Cash Flow Statement

Q Change in Cash / Investments

(445,804)

Balance Sheet

Q Cash / Investments

601,355

Q Short Term Debt

443,940

Q Long Term Debt

None

Q Total Current Assets

3.45M

Q Total Current Liabilities

4.35M

Q Total Assets

5.39M

Q Total Liabilities

5.57M

Q Stockholder Equity

(909,844)

NAVB Charts

10-Year Chart

NAVB 10-Year Chart

5-Year Chart

NAVB 5-Year Chart

1-Year Chart

NAVB 1-Year Chart

6-Month Chart

NAVB 6-Month Chart

3-Month Chart

NAVB 3-Month Chart

1-Month Chart

NAVB 1-Month Chart

1-Day Chart

NAVB 1-Day Chart

ACRX
Data Last Updated: 2 days ago

↻  Update Column 2 to Most Recent

Key Statistics

Cap: 88.033M


P/E: N/A

P/S: 38.44

Q P/B: N/A

Y Rev: 2.29M

Q Rev: 386,000

Beta: 1.81

ACRX Share Stats

Outstanding Shares

89.85M

Float Shares

78.92M

Percent of Float Short

14.95%

ACRX Insider Stats

Percent Outstanding Insider Ownership

3.14%

Percent Outstanding Institution Ownership

19.4%

ACRX Social Stats

Followers

0

B/S Rating Today

0

B/S Rating All-Time

N/A

More Social Data

ACRX in Pulse Portal

Stream of Posts

ACRX Symbol Page

Share ACRX Insights

Express Sentiment

'Buy' or 'Sell' ACRX

ACRX Profile

CEO

Mr. Vincent J. Angotti

Exchange

Nasdaq

Employees

99.00

About

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. Its products include sufentanil, DZUVEO, DSUVIA ZALVISO US and ZALVISO EU. The company was founded by Thomas A. Schreck and Pamela Pierce...

ACRX Financials

Annual Financials

Income Statement

Revenue

2.29M

Net Income

(53.24M)

Cash Flow Statement

Change in Cash / Investments

(73.29M)

Balance Sheet

Cash / Investments

66.14M

Short Term Debt

970,000

Long Term Debt

112.2M

Total Current Assets

71.69M

Total Current Liabilities

13.61M

Total Assets

91.36M

Total Liabilities

132.77M

Stockholder Equity

(41.42M)

Quarterly Financials

Income Statement

Q Revenue

386,000

Q Net Income

(15.93M)

Cash Flow Statement

Q Change in Cash / Investments

9.2M

Balance Sheet

Q Cash / Investments

52.73M

Q Short Term Debt

1.01M

Q Long Term Debt

109.93M

Q Total Current Assets

58.05M

Q Total Current Liabilities

15.72M

Q Total Assets

77.34M

Q Total Liabilities

132.62M

Q Stockholder Equity

(55.28M)

ACRX Charts

10-Year Chart

ACRX 10-Year Chart

5-Year Chart

ACRX 5-Year Chart

1-Year Chart

ACRX 1-Year Chart

6-Month Chart

ACRX 6-Month Chart

3-Month Chart

ACRX 3-Month Chart

1-Month Chart

ACRX 1-Month Chart

1-Day Chart

ACRX 1-Day Chart

 

 


Research

×
Stock Streams
Global Streams

UserStreamReactionsPulseStreamSpecStreamEchoStream
Stock Streams

Message BoardSpecStream TrendingTrending StocksTV Buzz

IPO Buzz (Pricings)IPO Buzz (Upcoming)Stocks Gapping HigherTrending Public Companies (Top Volume Generators)

Uplisted StocksNew 52-Week Highs (NASDAQ)New 52-Week Highs (NYSE)New 52-Week Highs (AMEX)

Technical IndicatorsUpgradesDowngradesRecent Earnings Surprises

Market Streams

Trending IndustriesETF's by SectorSectors Top to BottomCommodities

Economic IndicatorsStock ExchangesETF Movers
Premarket Streams

NASDAQ Premarket GainersNASDAQ Premarket LosersOverseas MarketsS&P Premarket Gainers & Losers

Morning Earning ReleasesFutures

After Hours Streams

After Hours GainersAfter Hours DeclinersAfter Hours Most ActiveAfter the Bell Earning Releases
Symbol Alert Streams

Market Cap MilestonesAbove Average VolumeCurrent Movers - GainersCurrent Movers - Decliners

Short Squeeze AlertsPrice to Earnings PE AlertsPrice to Sales PS AlertsPrice to Book PB Alerts

Insider Holding AlertsInstitutional Holding AlertsLow Float StocksProfitable or Not

Cash Flow PositiveHigh Beta Volatile Stocks

Media Streams

HeadlinesMedia BuzzEconomic NewsTop Stories
Social Streams

Pulse User 'Buys'Pulse User 'Sells'B/S Today Positive Sentiment MilestonesB/S Today Negative Sentiment Milestones

Stock Follower MilestonesStocks Followed by Users


Streams
Streams
            anon
   anon